GSK Management
Management criteria checks 3/4
GSK's CEO is Emma Walmsley, appointed in Apr 2017, has a tenure of 5.25 years. total yearly compensation is £8.20M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth CHF24.97M. The average tenure of the management team and the board of directors is 4.3 years and 5.2 years respectively.
Key information
Emma Walmsley
Chief executive officer
UK£8.2m
Total compensation
| CEO salary percentage | 14.9% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 4.3yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | UK£5b |
| Dec 31 2021 | UK£8m | UK£1m | UK£4b |
| Sep 30 2021 | n/a | n/a | UK£4b |
| Jun 30 2021 | n/a | n/a | UK£4b |
| Mar 31 2021 | n/a | n/a | UK£5b |
| Dec 31 2020 | UK£7m | UK£1m | UK£6b |
| Sep 30 2020 | n/a | n/a | UK£6b |
| Jun 30 2020 | n/a | n/a | UK£7b |
| Mar 31 2020 | n/a | n/a | UK£5b |
| Dec 31 2019 | UK£8m | UK£1m | UK£5b |
| Sep 30 2019 | n/a | n/a | UK£5b |
| Jun 30 2019 | n/a | n/a | UK£4b |
| Mar 31 2019 | n/a | n/a | UK£4b |
| Dec 31 2018 | UK£6m | UK£1m | UK£4b |
| Sep 30 2018 | n/a | n/a | UK£2b |
| Jun 30 2018 | n/a | n/a | UK£2b |
| Mar 31 2018 | n/a | n/a | UK£1b |
| Dec 31 2017 | UK£5m | UK£965k | UK£2b |
Compensation vs Market: Emma's total compensation ($USD9.86M) is above average for companies of similar size in the Swiss market ($USD6.38M).
Compensation vs Earnings: Emma's compensation has been consistent with company performance over the past year.
CEO
Emma Walmsley (52 yo)
5.3yrs
Tenure
UK£8,203,000
Compensation
Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | UK£8.20m | 0.031% CHF 25.0m | |
| CFO & Executive Director | 3.3yrs | UK£5.29m | 0.0055% CHF 4.5m | |
| Chief Scientific Officer | 4.3yrs | UK£9.26m | 0.023% CHF 18.5m | |
| Chief Digital & Technology Officer | 1.5yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Senior VP & Group General Counsel of Legal & Compliance | 3.9yrs | no data | no data | |
| Senior Vice President of Global Communications & CEO Office | 3.3yrs | no data | no data | |
| Chief People Officer | 3.3yrs | no data | no data | |
| Chief Strategy Officer | 14.2yrs | no data | no data | |
| President of Global Affairs | 5.3yrs | no data | 0.0030% CHF 2.4m | |
| President of Vaccines & Global Health | 9.5yrs | no data | no data | |
| Chief Executive Officer of GSK Consumer Healthcare | 5.8yrs | no data | no data |
4.3yrs
Average Tenure
56yo
Average Age
Experienced Management: 001102657's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.5yrs | UK£8.20m | 0.031% CHF 25.0m | |
| CFO & Executive Director | 3.5yrs | UK£5.29m | 0.0055% CHF 4.5m | |
| Chief Scientific Officer | 4.5yrs | UK£9.26m | 0.023% CHF 18.5m | |
| Non-Executive Chairman | 2.8yrs | UK£703.00k | 0.0014% CHF 1.1m | |
| Independent Non-Executive Director | 4.8yrs | UK£131.46k | 0.0010% CHF 824.1k | |
| Independent Non-Executive Director | 7.5yrs | UK£146.00k | 0.00036% CHF 293.7k | |
| Independent Non-Executive Director & Workforce Engagement Director | 6yrs | UK£136.00k | 0.00024% CHF 195.8k | |
| Senior Independent Non-Executive Director | 6.8yrs | UK£146.00k | 0.0021% CHF 1.7m | |
| Independent Non-Executive Director | 10yrs | UK£135.89k | 0.0019% CHF 1.5m | |
| Independent Non-Executive Director | 1.2yrs | UK£61.30k | 0.000040% CHF 32.6k | |
| Independent Non-Executive Director | 2.2yrs | UK£158.78k | 0.00041% CHF 334.5k | |
| Independent Non-Executive Director | 6.5yrs | UK£178.72k | 0.00045% CHF 367.2k |
5.2yrs
Average Tenure
63yo
Average Age
Experienced Board: 001102657's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/24 04:06 |
| End of Day Share Price | 2022/07/07 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GSK plc is covered by 64 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |